Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors

  • Authors:
    • Dal Rae Kim
    • Mi-Young Park
    • Hyo-Jeong Lim
    • Jong Sun Park
    • Young Jae Cho
    • Sei-Won Lee
    • Ho-Il Yoon
    • Jae-Ho Lee
    • Yeon-Soo Kim
    • Choon-Taek Lee
  • View Affiliations

  • Published online on: November 7, 2011     https://doi.org/10.3892/ijmm.2011.831
  • Pages: 218-224
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Combination therapy of adenoviral gene therapy and a histone deacetylase (HDAC) inhibitor is important due to the enhancing effect of HDAC inhibitors on adenoviral transduction and transcription. However, contradictory results have been reported on the effect of combination of CRAd (conditionally replicating adenovirus) and HDAC inhibitors. This study was designed to investigate the interaction of CRAd and HDAC inhibitors and determine the ideal way to combine the two agents. Combination of HDAC inhibitors (SK7041, SBHA and vorinostat) at pre- and post-transductional periods with CRAd enhanced the transduction of CRAd and expression of luciferase expression from Δ24-luc in vitro. However, suppression of luciferase expression from Δ24-luc injected tumor mass was observed by in vivo tumor bioluminescence imaging and drug interaction analysis also showed an antagonistic interaction that was probably related with the inhibitory effect of the HDAC inhibitor on adenoviral replication. Suppression of p21 induction by p21 siRNA reversed the suppressive effect of vorinostat on the replication of CRAd, but still failed to reverse the antagonistic interaction. Addition of vorinostat at the pre-transductional period revealed an improvement in the transduction efficiency of CRAd and also induced a synergistic interaction between CRAd and vorinostat, which was possibly related with prevention of the suppressive effect of vorinostat on adenoviral replication. In conclusion, the addition of HDAC inhibitor before CRAd injection showed synergistic antitumor effects, which warrants further investigation on the sequence of HDAC inhibitor and CRAd treatment in an animal tumor model.

Related Articles

Journal Cover

February 2012
Volume 29 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim DR, Park M, Lim H, Park JS, Cho YJ, Lee S, Yoon H, Lee J, Kim Y, Lee C, Lee C, et al: Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors. Int J Mol Med 29: 218-224, 2012.
APA
Kim, D.R., Park, M., Lim, H., Park, J.S., Cho, Y.J., Lee, S. ... Lee, C. (2012). Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors. International Journal of Molecular Medicine, 29, 218-224. https://doi.org/10.3892/ijmm.2011.831
MLA
Kim, D. R., Park, M., Lim, H., Park, J. S., Cho, Y. J., Lee, S., Yoon, H., Lee, J., Kim, Y., Lee, C."Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors". International Journal of Molecular Medicine 29.2 (2012): 218-224.
Chicago
Kim, D. R., Park, M., Lim, H., Park, J. S., Cho, Y. J., Lee, S., Yoon, H., Lee, J., Kim, Y., Lee, C."Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors". International Journal of Molecular Medicine 29, no. 2 (2012): 218-224. https://doi.org/10.3892/ijmm.2011.831